USPTO serial 97921045
UPTEMPO
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- EINSTEIN, MATTHEW T
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with UPTEMPO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $996*
Plus Government fees of $500
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Vanessa A. Ignacio, Esq.
Vanessa A. Ignacio, Esq. LOWENSTEIN SANDLER LLPONE LOWENSTEIN DRIVEROSELAND, NJ 07068United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Cells and cell lines for scientific, laboratory or medical research; Reagents for scientific or medical research use; Biological and biochemical preparations, namely, plasmids, RNA and proteins for scientific, medical research, or research use; Cell culture reagents for scientific and research use; Stem cells for research or scientific purposes; Biological preparations for use in cell cultures other than for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for use in scientific research and analysis | ACTIVE | — |
| 005 | Cells and cell lines for medical or clinical use; Stem cells for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, DNA plasmids, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; Pharmaceutical preparations in the nature of viral systems, gene therapy systems, and nucleic acid delivery systems comprised of viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells used to deliver modified genetic material into other cells for medical purposes | ACTIVE | — |
| 040 | Custom manufacture of cells and cell lines for use in viral vector production, and for diagnostic, medical and commercial applications in relation to cell and gene therapies | ACTIVE | — |
| 042 | Pharmaceutical research and development; Gene therapy research; Cell therapy research; Scientific research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CATALENT PHARMA SOLUTIONS, INC.
- Other trademarks owned by CATALENT PHARMA SOLUTIONS, INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named UPTEMPO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 14, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 21, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 21, 2026 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Nov 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 10, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 10, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 10, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 15, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 14, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 14, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 14, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 27, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 27, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 27, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 27, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 14, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 3, 2024 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Feb 13, 2024 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 23, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 23, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 3, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 21, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 20, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 4, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 8, 2023 | NWAP | NEW APPLICATION ENTERED | — |